新型冠状病毒感染对B细胞非霍奇金淋巴瘤的影响综述  

Effect of Coronavirus Disease 2019 infection on B-cell non-Hodgkin lymphoma

作　　者：吴炫璐 丁心 郑焱华 王晓雪[1] WU Xuanlu;DING Xin;ZHENG Yanhua;WANG Xiaoxue(Department of Hematology,the First Hospital Affilated to China Medical University,Shenyang,Liaoning,110000)

机构地区：[1]中国医科大学附属第一医院血液内科,辽宁沈阳110000

出　　处：《实用临床医药杂志》2024年第22期137-142,共6页Journal of Clinical Medicine in Practice

基　　金：国家自然科学基金项目(81900153);辽宁省科学技术基金项目(2022-YGJC-62)。

摘　　要：新型冠状病毒感染(COVID-19)是由严重急性呼吸道综合征冠状病毒2引起的一种传染病。B细胞淋巴瘤患者因疾病本身及其治疗可能导致免疫功能低下,成为COVID-19易感及重症的高危人群。因此,分析确诊COVID-19的B细胞非霍奇金淋巴瘤患者的基线特征、探究共同易感因素、评估疫苗接种效果及免疫治疗(尤其是CD20单抗)导致的免疫缺陷问题具有重要意义。针对发生COVID-19的B细胞非霍奇金淋巴瘤患者,需要进行个体化风险因素的评估。本综述就淋巴瘤患者对COVID-19的免疫应答展开阐述,总结发生COVID-19后的淋巴瘤患者特征,分析疫苗在这类群体中的有效性,探讨COVID-19对B细胞非霍奇金淋巴瘤病及抗肿瘤治疗的影响与相关风险因素,为拟定治疗策略及临床管理提供建议。Coronavirus Disease 2019(COVID-19)is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Patients with B-cell lymphoma may experience immunodeficiency due to the disease itself and its treatment,making them a high-risk group for susceptibility and severe outcomes of COVID-19.Therefore,it is crucial to analyze the baseline characteristics of B-cell non-Hodgkin lymphoma patients diagnosed with COVID-19,investigate common risk factors,evaluate the efficacy of vaccination and assess the immune deficiencies induced by immunotherapy,particularly CD20 monoclonal antibodies.For B-cell NHL patients with COVID-19,an individualized assessment of risk factors is necessary.This review discussed the immune response of lymphoma patients to COVID-19,summarized the characteristics of lymphoma patients following COVID-19,analyzed the vaccine effectiveness in this population,and explored the impact of COVID-19 on the onset and anti-tumor treatment of B-cell non-Hodgkin lymphoma,along with associated risk factors,aiming to provide recommendations for formulating treatment strategies and clinical management.

关 键 词：淋巴瘤 急性呼吸道综合征冠状病毒2 新型冠状病毒感染 CD20单抗 风险因素 病死率 

分 类 号：R551.2[医药卫生—血液循环系统疾病] R563.1[医药卫生—内科学] R329.2[医药卫生—临床医学]